Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel.

Davide Capodanno1, Marie-Claude Morice2, Dominick J Angiolillo3

  • 1Division of Cardiology, Azienda Ospedaliero Universitario "Policlinico G. Rodolico-San Marco", University of Catania, Catania, Italy.

Journal of the American College of Cardiology
|September 18, 2020
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between resting heart rate and clinical outcomes in heart failure with preserved ejection fraction: age stratified insights from the KUNIUMI Registry.

Heart and vessels·2026
Same author

Association of Tricuspid Regurgitation Severity With Activities of Daily Living and Dementia in Patients With Heart Failure: Insight from the KUNIUMI Registry Chronic Cohort.

Journal of cardiac failure·2026
Same author

Prognostic Impact of Annual Changes in the Geriatric Nutritional Risk Index in Malnourished Patients With Heart Failure.

Circulation reports·2025
Same author

Rituximab-induced long-term remission in childhood-onset, uncomplicated, frequently relapsing or steroid-dependent nephrotic syndrome: a randomized, placebo-controlled trial and a follow-up study.

Scientific reports·2025
Same author

Population Gap for Chronic Heart Failure Patients Between Randomized Controlled Trials and Japan's Super-Aged Society.

Circulation reports·2025
Same author

Patient-Reported Outcomes as End Points in Heart Failure Trials.

Circulation·2025
Summary

Balancing thrombotic and bleeding risks after percutaneous coronary intervention (PCI) is crucial for high bleeding risk (HBR) patients. This consensus document provides recommendations for designing clinical trials involving HBR patients undergoing PCI.

Area of Science:

  • Cardiology
  • Clinical Trial Design
  • Interventional Cardiology

Background:

  • Patients undergoing percutaneous coronary intervention (PCI) often face a delicate balance between thrombotic and bleeding risks.
  • High bleeding risk (HBR) patients represent a vulnerable population requiring specialized clinical trial considerations.
  • The Academic Research Consortium for HBR has established a consensus definition to standardize HBR patient identification in trials.

Purpose of the Study:

  • To propose evidence-based recommendations for designing clinical trials focused on HBR patients undergoing PCI.
  • To guide the development of future trials evaluating drugs and devices in this specific patient group.
  • To standardize trial methodologies for assessing outcomes in HBR patients undergoing PCI.

Main Methods:

Keywords:
high bleeding riskpercutaneous coronary interventiontrial design

Related Experiment Videos

  • Consensus-based document development by the Academic Research Consortium for HBR.
  • Review and discussion of existing trial designs for HBR patients undergoing PCI.
  • Identification of key aspects for optimizing trial design, including population, interventions, and outcomes.

Main Results:

  • The document outlines critical considerations for HBR patient trial design.
  • Specific recommendations are provided for target populations, intervention and control groups.
  • Guidance is offered on primary and secondary outcomes, and the timing of endpoint reporting.

Conclusions:

  • Standardized trial designs are essential for accurately evaluating interventions in HBR patients undergoing PCI.
  • The proposed recommendations aim to enhance the quality and relevance of clinical trials in this field.
  • This initiative facilitates a more robust understanding of managing thrombotic and bleeding risks in HBR populations.